Brooks Laboratories Share Price Live
Live Brooks Laboratories Share Price Chart
Brooks Laboratories Performance
Days Range
| Previous Close | ₹105.15 |
|---|---|
| Open | ₹105.6 |
| Volume | 15,867 |
| Day's Range | ₹101.89 - ₹105.60 |
|---|---|
| 52W Range | ₹95.55 - ₹198.86 |
| Market Cap | ₹310.63 Cr |
Brooks Laboratories Fundamentals
| ROCE(TTM) | 12.32 |
|---|---|
| P/E Ratio (TTM) | 22.25 |
| P/B Ratio | 2.69 |
| Industry P/E | 33.19 |
| Debt to Equity | 0.07 |
| ROE | 12.08 |
| EPS (TTM) | 4.74 |
| Dividend Yield | 0 |
| Book Value | 39.27 |
| Face Value | 10 |
| ROCE(TTM) | 12.32 |
|---|---|
| P/E Ratio (TTM) | 22.25 |
| P/B Ratio | 2.69 |
| Industry P/E | 33.19 |
| Debt to Equity | 0.07 |
| ROE | 12.08 |
|---|---|
| EPS (TTM) | 4.74 |
| Dividend Yield | 0 |
| Book Value | 39.27 |
| Face Value | 10 |
Brooks Laboratories Financials
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | |
|---|---|---|---|---|
| Net Sales | 20.52 | 23.32 | 25.51 | 23.45 |
| Expenses | 19.32 | 22.16 | 22.78 | 21.32 |
| Profit before tax | -2.13 | -1.28 | 9.58 | 7.98 |
| Operating Profit | -2.13 | -1.46 | 9.58 | 7.98 |
| Net Profit | -2.13 | -1.46 | 9.58 | 7.98 |
| ESP in Rs | -1.75 | -0.54 | 3.25 | 2.71 |
Brooks Laboratories Shareholding Pattern
| Held by | Dec 2024 | Jan 2025 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|
| Promoters | 59.06% | 52.62% | 52.62% | 52.62% | 52.62% |
| Flls | 0.01% | 0% | 0.05% | 0% | 0.01% |
| Dlls | 3.86% | 9.9% | 10.38% | 10.38% | 10.38% |
| Public | 37.08% | 37.48% | 36.95% | 37% | 37% |
About Brooks Laboratories
Brooks Laboratories Ltd is a Pharmaceutical Contract Research & Manufacturing Services company. The company has a wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General Dry powder Injectables, Ampoules and Liquid vials, Dry Syrups and Tablets etc. Their product portfolio presently comprises of 28 Injectables, 19 Tablets and 2 Dry Syrups which are marketed domestically.
The company has manufacturing facilities located at Baddi in Himachal Pradesh. Their manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes. Their Baddi facility is a WHO-GMP and ISO-9001:2008 certified. At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India.
The company's major clients are companies like Zydus Cadila, Aristo Pharmaceuticals Pvt Ltd, FDC Ltd, Nectar Lifesciences Ltd, Sanat Products Ltd, Hetero Healthcare Ltd, Medley Pharmaceuticals, Wockhardt Ltd, Parental Drugs, Chanderbhagat Pharma and Alembic Ltd etc. Their major suppliers of raw materials are Rajasthan Antibiotics Ltd, Aurobindo Pharma Ltd, DSM Anti Infectives Ltd and Qilu Pharmaceutical Company Ltd.
Brooks Laboratories Ltd was incorporated on January 23, 2002. The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers.
In the year 2006, the company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development (R&D) centre at Baddi, Himachal Pradesh. In May 2006, they started their operations and in June 3, 2006, they commenced commercial production.
In October 2006, the company obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. In August 2007, they received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Ltd, Australia. In April 2008, the company took over some of the assets of Brooks Pharmaceuticals, a partnership firm of the promoters, Atul Ranchal & Rajesh Mahajan.
In April 2010, the manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health & Family Welfare, HP. In July 2010, the company received an ISO 9001:2008 Certificate from UKAS Quality Management, URS & IAF.
The company plans to set up a facility at JB SEZ, Panoli, Gujarat for manufacturing of various pharmaceuticals formulations in compliance with EU GMP Standards to cater to high end market of Europe, CIS & South Africa.
Parent Organisation
Indian Private
Managing Director
None
Founded
2002
NSE Symbol
BROOKS
Top Mutual Funds Invested in Brooks Laboratories Share
Top Mutual Funds Invested in Brooks Laboratories Share
Peer Comparison
Peer Comparison
| Stocks | LTP (₹) | Market Cap (cr) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 1,779.5 2.10 (0.12%) | ₹4,26,565.77 | 1,548.0 - 1,910.0![]() |
| Divis Laboratories Ltd | 6,379.0 -83.50 (-1.29%) | ₹1,71,593.58 | 4,955.0 - 7,071.5![]() |
| Torrent Pharmaceuticals Ltd | 3,681.6 -39.80 (-1.07%) | ₹1,25,819.90 | 2,886.45 - 3,882.2![]() |
| Cipla Ltd | 1,512.1 -17.10 (-1.12%) | ₹1,23,504.18 | 1,335.0 - 1,673.0![]() |
| Dr Reddys Laboratories Ltd | 1,242.5 -6.10 (-0.49%) | ₹1,04,131.51 | 1,020.0 - 1,405.9![]() |
| Zydus Lifesciences Ltd | 924.7 -3.30 (-0.36%) | ₹93,338.26 | 795.0 - 1,059.05![]() |
Popular stocks
Brooks Laboratories Ltd FAQs
What is the share price of Brooks Laboratories Ltd (BROOKS) shares?
Brooks Laboratories Ltd (BROOKS) share price as of November 21, 2025, on NSE is Rs 102.34 (NSE) and Rs 102.34 (BSE) on BSE.
Can I buy Brooks Laboratories Ltd (BROOKS) from Angel One?
Yes, You can buy Brooks Laboratories Ltd (BROOKS) shares by opening a Demat account with Angel One.
How do I buy Brooks Laboratories Ltd (BROOKS) from Angel One?
Brooks Laboratories Ltd (BROOKS) share can be bought through the following modes:
1. Direct investment: You can buy Brooks Laboratories Ltd (BROOKS) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Brooks Laboratories Ltd (BROOKS) shares.
1. Direct investment: You can buy Brooks Laboratories Ltd (BROOKS) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Brooks Laboratories Ltd (BROOKS) shares.




